Praveen was previously President and CEO of Morphic Therapeutic Inc. which he led from its founding to acquisition by Eli Lilly for $3.2 billion. Previously, he was Senior Vice President of Corporate Development and Global Strategy at Cubist Pharmaceuticals, a position in which he served from 2006 until the company’s acquisition by Merck in 2015 for approximately $9 billion. He previously served in the clinical group working on the Cubicin NDA (skin and skin structure infections) and sNDA (Staph. Bacteremia and Endocarditis) teams since 2002. Cubicin hit peak sales of $1.2 billion. He also served time as a 1st Lieutenant in the U.S. Army. Praveen received a bachelor’s degree from MIT in mechanical engineering and an M.D. from McGill University. After completing his post-graduate residency in Internal Medicine at University of Illinois, Chicago, he received his MBA from the University of Pennsylvania’s Wharton School of Business in healthcare finance.